Skip to main content
Publications
Moehler M, Wyrwicz L, Chen C, Davenport E , Wang J , Nathani R, Kondo K, Elimova E. Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) vs (C) . Poster presented at the 2024 German Cancer Congress (Deutscher Krebskongress); February 21, 2024. Berlin, Germany. [abstract] Oncol Res Treat. 2024; 41(Supple 1):65. Previously presented at the 2023 ASCO Annual Meeting.
Swertz M, van Enckevort E, Oliveira JL, Fortier I, Bergeron J, Thurin NH, Hyde E, Kellmann A, Pajouheshnia R , Sturkenboom M, Cunnington M, Nybo Andersen A-M, Marcon Y, Goncalves G, Gini R. Towards an interoperable ecosystem of research cohort and real-world data catalogues enabling multi-center studies . Yearb Med Inform. 2022 Aug;31(1):262-72. doi: 10.1055/s-0042-1742522
Todenhofer T, Fizazi K, Shore ND, Tammela T, Kuss I, Le Barre M-A, Mohammed AF, Odom D , Bartsch J , Snapir A, Sarapohja T, Smith MR. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (PTS) with nonmetastatic castrate-resistant prostate cancer (NMCRPC) . Poster presented at the 2020 German Cancer Congress; February 2020. [abstract] Oncol Res Treat. 2020 Feb; 43(Suppl 1):154-5. Previously presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.